OVID THERAPEUTICS INC (OVID) Stock Fundamental Analysis

NASDAQ:OVID • US6904691010

1.63 USD
-0.02 (-1.21%)
At close: Feb 27, 2026
1.59 USD
-0.04 (-2.45%)
After Hours: 2/27/2026, 8:25:44 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall OVID gets a fundamental rating of 3 out of 10. We evaluated OVID against 520 industry peers in the Biotechnology industry. The financial health of OVID is average, but there are quite some concerns on its profitability. OVID is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year OVID has reported negative net income.
  • OVID had a negative operating cash flow in the past year.
  • In the past 5 years OVID reported 4 times negative net income.
  • In the past 5 years OVID reported 4 times negative operating cash flow.
OVID Yearly Net Income VS EBIT VS OCF VS FCFOVID Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -56.90%, OVID is in line with its industry, outperforming 44.06% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -81.28%, OVID is in line with its industry, outperforming 50.77% of the companies in the same industry.
Industry RankSector Rank
ROA -56.9%
ROE -81.28%
ROIC N/A
ROA(3y)-33.31%
ROA(5y)-29.01%
ROE(3y)-46.44%
ROE(5y)-51.69%
ROIC(3y)N/A
ROIC(5y)N/A
OVID Yearly ROA, ROE, ROICOVID Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for OVID so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OVID Yearly Profit, Operating, Gross MarginsOVID Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • OVID does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • OVID has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for OVID has been increased compared to 5 years ago.
  • OVID has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
OVID Yearly Shares OutstandingOVID Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
OVID Yearly Total Debt VS Total AssetsOVID Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • OVID has an Altman-Z score of -2.21. This is a bad value and indicates that OVID is not financially healthy and even has some risk of bankruptcy.
  • OVID has a Altman-Z score of -2.21. This is comparable to the rest of the industry: OVID outperforms 48.85% of its industry peers.
  • OVID has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.21
ROIC/WACCN/A
WACC8.61%
OVID Yearly LT Debt VS Equity VS FCFOVID Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 4.24 indicates that OVID has no problem at all paying its short term obligations.
  • OVID has a Current ratio of 4.24. This is comparable to the rest of the industry: OVID outperforms 50.19% of its industry peers.
  • A Quick Ratio of 4.24 indicates that OVID has no problem at all paying its short term obligations.
  • OVID has a Quick ratio (4.24) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.24
Quick Ratio 4.24
OVID Yearly Current Assets VS Current LiabilitesOVID Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • OVID shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.38%.
  • Looking at the last year, OVID shows a very strong growth in Revenue. The Revenue has grown by 946.55%.
  • Measured over the past years, OVID shows a very negative growth in Revenue. The Revenue has been decreasing by -86.05% on average per year.
EPS 1Y (TTM)-6.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15%
Revenue 1Y (TTM)946.55%
Revenue growth 3Y-86.05%
Revenue growth 5YN/A
Sales Q2Q%-23.7%

3.2 Future

  • The Earnings Per Share is expected to decrease by -3.38% on average over the next years.
  • OVID is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 63.21% yearly.
EPS Next Y-30.82%
EPS Next 2Y-10.7%
EPS Next 3Y-12.9%
EPS Next 5Y-3.38%
Revenue Next Year892.86%
Revenue Next 2Y-49.61%
Revenue Next 3Y-47.73%
Revenue Next 5Y63.21%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
OVID Yearly Revenue VS EstimatesOVID Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M
OVID Yearly EPS VS EstimatesOVID Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • OVID reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year OVID is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OVID Price Earnings VS Forward Price EarningsOVID Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OVID Per share dataOVID EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4

4.3 Compensation for Growth

  • A cheap valuation may be justified as OVID's earnings are expected to decrease with -12.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.7%
EPS Next 3Y-12.9%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • OVID does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

OVID THERAPEUTICS INC

NASDAQ:OVID (2/27/2026, 8:25:44 PM)

After market: 1.59 -0.04 (-2.45%)

1.63

-0.02 (-1.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-16
Inst Owners33.76%
Inst Owner Change96.3%
Ins Owners3.07%
Ins Owner Change0.56%
Market Cap212.19M
Revenue(TTM)6.61M
Net Income(TTM)-36.33M
Analysts87.5
Price Target4.26 (161.35%)
Short Float %4.12%
Short Ratio3.11
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)26.21%
Min EPS beat(2)-11.2%
Max EPS beat(2)63.62%
EPS beat(4)2
Avg EPS beat(4)18.8%
Min EPS beat(4)-11.2%
Max EPS beat(4)63.62%
EPS beat(8)5
Avg EPS beat(8)-9.79%
EPS beat(12)8
Avg EPS beat(12)-3.55%
EPS beat(16)11
Avg EPS beat(16)1.7%
Revenue beat(2)1
Avg Revenue beat(2)3959.29%
Min Revenue beat(2)-1.54%
Max Revenue beat(2)7920.11%
Revenue beat(4)2
Avg Revenue beat(4)2003.21%
Min Revenue beat(4)-60.64%
Max Revenue beat(4)7920.11%
Revenue beat(8)6
Avg Revenue beat(8)1066.77%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0.6%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.95%
EPS NY rev (1m)0%
EPS NY rev (3m)-6.41%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.36%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 32.1
P/FCF N/A
P/OCF N/A
P/B 4.75
P/tB 4.75
EV/EBITDA N/A
EPS(TTM)-0.5
EYN/A
EPS(NY)-0.47
Fwd EYN/A
FCF(TTM)-0.29
FCFYN/A
OCF(TTM)-0.29
OCFYN/A
SpS0.05
BVpS0.34
TBVpS0.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -56.9%
ROE -81.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.31%
ROA(5y)-29.01%
ROE(3y)-46.44%
ROE(5y)-51.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -1%
Cap/Sales 0.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.24
Quick Ratio 4.24
Altman-Z -2.21
F-Score3
WACC8.61%
ROIC/WACCN/A
Cap/Depr(3y)104.96%
Cap/Depr(5y)109.64%
Cap/Sales(3y)52.29%
Cap/Sales(5y)32.03%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15%
EPS Next Y-30.82%
EPS Next 2Y-10.7%
EPS Next 3Y-12.9%
EPS Next 5Y-3.38%
Revenue 1Y (TTM)946.55%
Revenue growth 3Y-86.05%
Revenue growth 5YN/A
Sales Q2Q%-23.7%
Revenue Next Year892.86%
Revenue Next 2Y-49.61%
Revenue Next 3Y-47.73%
Revenue Next 5Y63.21%
EBIT growth 1Y41.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year9.56%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.78%
OCF growth 3YN/A
OCF growth 5YN/A

OVID THERAPEUTICS INC / OVID FAQ

Can you provide the ChartMill fundamental rating for OVID THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to OVID.


What is the valuation status of OVID THERAPEUTICS INC (OVID) stock?

ChartMill assigns a valuation rating of 0 / 10 to OVID THERAPEUTICS INC (OVID). This can be considered as Overvalued.


What is the profitability of OVID stock?

OVID THERAPEUTICS INC (OVID) has a profitability rating of 1 / 10.


What is the financial health of OVID THERAPEUTICS INC (OVID) stock?

The financial health rating of OVID THERAPEUTICS INC (OVID) is 6 / 10.


What is the earnings growth outlook for OVID THERAPEUTICS INC?

The Earnings per Share (EPS) of OVID THERAPEUTICS INC (OVID) is expected to decline by -30.82% in the next year.